Rapid and simultaneous measurement of midazolam, 1′-hydroxymidazolam and digoxin by liquid chromatography/tandem mass spectrometry: Application to an in vivo study to simultaneously measure P-glycoprotein and Cytochrome P450 3A activity

Journal of Pharmaceutical and Biomedical Analysis

Volumn 55, Issue 1, 2011, Pages 187-193

  Xue, Xinping ^a   Huang, Min ^a   Xiao, Huanyu ^a   Qin, Xiaoling ^a   Huang, Ling ^a   Zhong, Guoping ^a   Bi, Huichang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

1 Hydroxymidazolam (1 OHMDZ); Cytochrome P450 3A (CYP3A); Digoxin (DG); Liquid chromatography tandem mass spectrometry (LC MS MS); Midazolam (MDZ); P glycoprotein (P gp)

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A; DICHLOROMETHANE; DIGOXIN; GLYCOPROTEIN P; MIDAZOLAM; TERT BUTYL METHYL ETHER;

ACCURACY; ARTICLE; CALIBRATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; ELECTROSPRAY; ENZYME ACTIVITY; FRAGMENTATION REACTION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; QUALITY CONTROL; RAT; TANDEM MASS SPECTROMETRY;

ANIMALS; BIOTRANSFORMATION; CALIBRATION; CARDIOTONIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; DIGOXIN; DRUG INTERACTIONS; DRUG STABILITY; LIMIT OF DETECTION; MALE; MIDAZOLAM; P-GLYCOPROTEIN; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 79951771539     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.01.018     Document Type: Article

References (24)

1. Wacher V.J., Wu C.Y., Benet L.Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 1995, 13:129-134.
2. Kim R.B., Wandel C., Leake B., Cvetkovic M., Fromm M.F., Dempsey P.J., Roden M.M., Belas F., Chaudhary A.K., Roden D.M., Wood A.J., Wilkinson G.R. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 1999, 16:408-414.
3. Nordt S.P., Clark R.F. Midazolam: a review of therapeutic uses and toxicity. J. Emerg. Med. 1997, 15:357-365.
4. Kronbach T., Mathys D., Umeno M., Gonzalez F.J., Meyer U.A. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 1989, 36:89-96.
5. Kato R., Yamashita S., Moriguchi J., Nakagawa M., Tsukura Y., Uchida K., Amano F., Hirotani Y., Ijiri Y., Tanaka K. Changes of midazolam pharmacokinetics in Wistar rats treated with lipopolysaccharide: relationship between total CYP and CYP3A2. Innate Immun. 2008, 14:291-297.
6. Kirby B., Kharasch E.D., Thummel K.T., Narang V.S., Hoffer C.J., Unadkat J.D. Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities. J. Clin. Pharmacol. 2006, 46:1313-1319.
7. Klein W., Eber B., Rotman B. Comparative effects of digoxin and xamoterol on arrhythmias in patients with mild to moderate heart failure. Angiology 1992, 43:281-286.
8. Hori R., Okamura N., Aiba T., Tanigawara Y. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J. Pharmacol. Exp. Ther. 1993, 266:1620-1625.
9. Ben R.M., Bonhomme-Faivre L., Orbach-Arbouys S., Farinotti R. Modification of the P-glycoprotein dependent pharmacokinetics of digoxin in rats by human recombinant interferon-alpha. Pharm. Res. 2005, 22:1829-1836.
10. Cem K.Y., Kubilay O., Ozlem E., Hulya E., Ayse G. Effect of repeated low-dose organophosphorothionate pesticide exposure on digoxin pharmacokinetics in rats; a possible interaction involving P-glycoprotein. Toxicol. Mech. Methods 2007, 17:459-466.
11. Jurica J., Dostalek M., Konecny J., Glatz Z., Hadasova E., Tomandl J. HPLC determination of midazolam and its three hydroxy metabolites in perfusion medium and plasma from rats. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 852:571-577.
12. Liu Y., Jiao J., Zhang C., Lou J. A simplified method to determine five cytochrome p450 probe drugs by HPLC in a single run. Biol. Pharm. Bull. 2009, 32:717-720.
13. Kumar A., Mann H.J., Remmel R.P. Simultaneous analysis of cytochrome P450 probes-dextromethorphan, flurbiprofen and midazolam and their major metabolites by HPLC-mass-spectrometry/fluorescence after single-step extraction from plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 853:287-293.
14. Link B., Haschke M., Wenk M., Krahenbuhl S. Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2007, 21:1531-1540.
15. Harris S.R., Gedge J.I., Nedderman A.N., Roffey S.J., Savage M. A sensitive HPLC-MS-MS assay for quantitative determination of midazolam in dog plasma. J. Pharm. Biomed. Anal. 2004, 35:127-134.
16. Muchohi S.N., Ward S.A., Preston L., Newton C.R., Edwards G., Kokwaro G.O. Determination of midazolam and its major metabolite 1′-hydroxymidazolam by high-performance liquid chromatography-electrospray mass spectrometry in plasma from children. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005, 821:1-7.
17. Ikeda Y., Araki T., Takimoto H., Fujii Y. Development of radioimmunoassay for measurement of serum digoxin in digitalized patients using novel anti-digoxin antiserum. Biol. Pharm. Bull. 2002, 25:422-425.
18. Davey C.L., Thakkar H., Newman D.J., Price C.P. A simple, automated, nonextraction assay for serum digoxin using particle-enhanced immunoassay. Ther. Drug Monit. 1997, 19:108-111.
19. Jedlicka A., Grafnetterova T., Miller V. HPLC method with UV detection for evaluation of digoxin tablet dissolution in acidic medium after solid-phase extraction. J. Pharm. Biomed. Anal. 2003, 33:109-115.
20. Varma M.V., Kapoor N., Sarkar M., Panchagnula R. Simultaneous determination of digoxin and permeability markers in rat in situ intestinal perfusion samples by RP-HPLC. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2004, 813:347-352.
21. Yao M., Zhang H., Chong S., Zhu M., Morrison R.A. A rapid and sensitive LC/MS/MS assay for quantitative determination of digoxin in rat plasma. J. Pharm. Biomed. Anal. 2003, 32:1189-1197.
22. Hashimoto Y., Shibakawa K., Nakade S., Miyata Y. Validation and application of a 96-well format solid-phase extraction and liquid chromatography-tandem mass spectrometry method for the quantitation of digoxin in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 869:126-132.
23. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75:3019-3030.
24. Bi H.C., Zhao L.Z., Zhong G.P., Zhou S., Li B., Deng Y., Chen X., Huang M. High-throughput determination of carbocysteine in human plasma by liquid chromatography/tandem mass spectrometry: application to a bioequivalence study of two formulations in healthy volunteers. Rapid Commun. Mass Spectrom. 2006, 20:1153-1160.